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ABSTRACT 
Age-related macular degeneration (AMD) is becoming the leading cause of blindness in developed 
countries. The exact etiology and pathophysiology of AMD is still unclear. A number of risk factors of AMD 
have been recognized, such as cigarette smoking, a family history of AMD and being Caucasian. On the 
other hand, aspirin is a widespread medication, which is thought to be associated with the prevalence or 
the survival of myocardial infarction and cancers. However, the evidence from the epidemiological studies 
has been contradictory and no persuasive conclusions have been made. Several problems, such as the 
parameters of aspirin use, the inclusion and exclusion of the participants and the required long-term 
follow-up, made it hard to conclude a definite relationship between aspirin use and AMD. Aspirin, as an 
anti-inflammatory agent, could prevent the inflammation and decrease the inflammatory damage, and 
might act as a deterrent for the progression of AMD. However, aspirin is an anticoagulant which might 
increase the risk of ocular hemorrhage in AMD patients. Decades ago, the use of aspirin was reported 
associated with decreased rates of CNV among AMD patients nevertheless recently, the association 
between aspirin use and increased risk of neovascular AMD was identified. Therefore, these current results 
should be challenged and acknowledged by well-designed, large-scale and long term follow-up studies. A 
consultation might be needed when aspirin is used in the neovascular AMD patients. 
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INTRODUCTION 
Age-related macular degeneration (AMD), which was first 
introduced in 1875 in medical literature, is now regarded 
as one of the most common cases of blindness [1]. The 
prevalence of AMD increased exponentially each decade 
after fifth decades of age [2] and in the developed areas, 
AMD was the cause of more than half of the blind in the 
elderly [3]. Furthermore, AMD is a progressive disease 
and multifactorial condition in terms of etiology. Other 
than age and genetic predisposition, several 
epidemiologic risk factors such as cigarette smoking, 
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family history of AMD and Caucasian race were also 
reported [4, 5]. Besides, several systemic disorders 
including hypertension, cardiovascular disease, stroke, 
and diabetes mellitus were associated with the incidence 
of AMD as reported by several studies [6-9]. However, 
the associations between systemic diseases with AMD 
were inconsistent in each study. It should be noted that 
more research is required to get further evidence on 
these theories and pathophysiology of the disease. 
The etiology and pathophysiology of AMD remain 
unclear. In general, AMD is a multifactorial disease in 
which oxidative damage, inflammatory reaction and 
abnormal immune response are involved [8, 10, 11]. The 
understanding of the pathophysiology of AMD has 
improved through several studies however the attributes 
of each pathological causal agent on the progress of AMD 
is largely unknown. It is because of the complexity of the 
etiology and pathology of AMD that effective therapy 
and prophylaxis have yet to be developed. Anti-VEGF 
therapy is regarded as effective for the wet AMD 
patients, however, it is still not a curative therapy [12]. 
Further research on the detection of the core 
pathophysiology of AMD is required. 
Clinical researches are detecting the association between 
certain factors and AMD. The results of clinical research, 
in turn, would lead to advanced understanding of the 
pathology and potential improved therapy. Aspirin is a 
widespread medication which is associated with the 
prevalence or the survival of myocardial infarction and 
cancers [13-15]. The association between aspirin use and 
risk of AMD was reported in several cross-sectional 
studies, while no accordant conclusion was obtained [16, 
17]. We conducted a meta-analysis through pooling the 
relevant studies together and no significant results were 
detected [18]. However, taking the inherent limitations 
of that meta-analysis into account, the conclusion should 
be considered with caution. Recently, several well-
designed large-sample studies reported the association 
between aspirin use and risk of AMD and demonstrated 
valuable and interesting results [19-21]. The purpose of 
this manuscript is to review the association between 
aspirin use and the risk of AMD.  
Classification and Clinical symptoms of AMD 
Two hallmarks, presence of drusen and choroidal 
neovascularization (CNV), are of great importance in the 
diagnoses and classification of AMD. Drusen is usually 
the first detected clinical finding in AMD and the 
presence of CNV is a sign of an aggravated AMD state 
[22, 23]. According to the former studies, drusen are 
classified by the diameter as small (<63 μm), medium (63 
to 124 μm) and large (>124 μm). Several clinical 
classifications exist nowadays and the most often used is 
the classification proposed by the Age-Related Eye 
Disease Study (AREDS, supported by the National 
Institutes of Health) [24]. A total of five categories of 
AMD are defined: asymptomatic AMD; early AMD; 
intermediated AMD; advanced non-neovascular AMD 
and advanced neovascular AMD. In the early AMD, only a 
few medium-size drusen presented while in the 
intermediate AMD, numerous medium-size and at least 
one large drusen presented. However, the center of the 
macular hasn’t been involved. In the advanced non-
neovascular AMD, the center of macular is involved. The 
presence of CNV and its complications demonstrates the 
advanced neovascular AMD.  
In the early stage of AMD, the damage of visual acuity 
and visual function is not apparent and quite a few 
patients are diagnosed from routine examinations. 
However, the presence of advanced AMD, especially the 
neovascular AMD, is a significant threat to the vision. 
Appropriate measures should be conducted in all the 
different stages [25]. 
Pathophysiology of AMD 
As defined beforehand, the pathophysiology of AMD is 
still unclear. AMD is a progressive disease, which affects 
retinal pigment epithelium (RPE), photoreceptors, 
Bruch’s membrane and choriocapillaris [1]. Several 
pathologic processes, including oxidative damage, 
inflammatory reaction and abnormal immune response, 
are regarded as core in the progression of AMD. 
Oxidative response, which plays a key role in numerous 
diseases, works in the development and progression of 
AMD. The epidemiological research demonstrated that a 
reduced exposure to an oxidative environment and the 
additional supplementation of antioxidant diet/drug 
would reduce the prevalence and progression of AMD 
[26-28]. The visual acuity impairment often occurs when 
photoreceptor, RPE, and Bruch’s membrane are 
damaged by the oxidative stress [29]. More research has 
reported the extended effects of oxidative response on 
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AMD which provided novel theories on the 
pathophysiology of AMD [30].  
It is widely accepted that inflammation plays an 
important role in the development and progression of 
AMD [31, 32]. Some inflammatory markers, such as C-
reactive protein, intercellular adhesion molecule, 
interleukin-6, are abnormally expressed in the AMD 
cases [33-36]. Furthermore, some inflammatory cells, 
including macrophages and microglia, were involved in 
the AMD [37, 38]. Considering that AMD is not a classical 
inflammatory disease, more studies required to be 
focused on the effects of parainflammation in the AMD 
[39]. Parainflammation is defined as an adaptive 
response to stress, such as aging, oxidative stress and 
oxidized lipoproteins [40]. It is a condition between 
normality and acute inflammation, which functions as a 
path to maintain the normal retina and restore the 
damaged tissues [41]. In general, it is regarded as a 
beneficial effect. However, it should also be noted that 
the abnormal parainflammation is probably a cause of 
the onset or progression of AMD [42, 43]. Several studies 
had aimed to treat AMD by targeting the inflammatory 
pathway. IL-10 regulates macrophage activity, which 
shows the potential to be a therapeutic target. An IL-10 
knocked-down mouse is used as an animal model of CNV 
caused by AMD. The anti-inflammatory intervention 
revealed improvement of the CNV [44]. Recombinant 
TSG-6, as an anti-inflammatory protein, showed the 
effect of treating AMD through an intravitreous injection 
into the animal model [45]. However, it is a long way to 
develop a definitive and substantial treatment of AMD by 
focusing on the inflammatory reactions. 
Although the eye is an “immune-privileged” site, AMD is 
regarded as immune mediated disease as well [46]. 
Various evidences exist about the role of immune 
reaction on the AMD. Histological study of drusen and 
CNV proved that immunologic dysfunction also existed in 
humans [47]. The complement system, which is part of 
immune system, is thought to play an important role in 
the development of AMD [48]. Furthermore, several 
other immune components, such as antigen presenting 
cells, also contribute to AMD [49]. Nowadays, AMD is 
considered to be a systemic immunologic disease with 
local expression. Thus therapeutic strategies should be 
changed. In the future, advanced research on the trigger 
mechanisms would beneficial to develop more effective 
therapies for AMD. 
General Mechanism of Aspirin Action 
Aspirin is a classical non-steroidal anti-inflammatory drug 
(NSAIDs), which works through both cyclooxygenase 
(COX)-dependent pathways and COX-independent 
pathways. In the COX-dependent pathway, aspirin 
inhibits both COX-1 and COX-2 irreversibly. Cox converts 
arachidonic acid to prostaglandin H2 and the inhibition of 
COX will lead to a decreased expression of prostanoids 
including prostaglandin (PG)D2, PGF2α and PGE2, 
thromboxane A (TXA2) and prostacyclin (PGI2) [50]. 
Prostanoids demonstrate a wide range of biological 
functions including cell proliferation and migration, 
angiogenesis, apoptosis, and inflammatory response [51-
53]. Thus, it could be concluded that aspirin played a role 
in these aspects. 
Aspirin can also function through COX-independent 
pathways. The most accepted pathway is the inhibition 
of transcription factor nuclear factor κb (NFκB) [54]. 
Besides, other mechanisms of the actions of aspirin were 
also reported such as induction of apoptosis, DNA 
stabilization, TNF-α and TGF-β expression, induction of 
heme oxygenase-1 (HO-1) and Wnt signaling [55-58]. 
Aspirin and AMD — Evidence from Experimental 
Research 
AMD is a multifactorial disease consisting of various 
kinds of pathologic processes. Aspirin is a drug with 
various pharmacological effects. It is logical to conclude 
that aspirin could produce some effects on the AMD. 
However, the direct evidence about the relationship 
between aspirin use and the development of AMD are 
unproven. We can only presume the possible effects of 
aspirin on AMD from the current experimental research.  
Firstly, aspirin might generate some beneficial effects by 
delaying the progression of AMD. Inflammation is a core 
physiopathological factor in AMD. The proinflammatory 
genes such as COX-2, MCP-1 and IL-8 are up-regulated in 
AMD [59]. Aspirin, which is an anti-inflammatory agent, 
could prevent the inflammation and decrease the 
inflammatory damage. Considering that aspirin might 
affect through the COX-independent pathway, more 
specific results are expected. NFκB is a key target of 
aspirin in the COX-independent pathway [60, 61]. Other 
target sites of aspirin, such as Wnt and HO-1 pathways, 
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were also reported to be related with AMD [62, 63]; they 
are the possible linkages between aspirin and AMD. 
However, all the presumptions above are based 
independent experiments. More relevant, directed and 
well-designed experiments are required as proof. 
Therefore, the opinion that aspirin is a protectant for 
AMD should be considered with caution. 
However, harmful effects might be produced by aspirin 
on AMD as well. A most recent study revealed that a 
NSAID, which is a meclofenamic acid, would block the 
gap junction communication between the RPE cells. This 
phenomenon was also observed in other NSAIDs, 
including aspirin [64]. It presumed that the damaged 
retinal microenvironment would worsen the progression 
of AMD. Considering that aspirin has a widespread use as 
an anticoagulant, the risk of ocular hemorrhage is 
predicted to increase in AMD patients, especially in the 
neovascular AMD patients. Also, the parainflammation in 
AMD might interfere with restoration and 
reconstruction. Considering no powerful evidence of the 
definitive effects of aspirin on AMD, the beneficial or 
harmful effects of aspirin on the AMD have not been 
reasonably evaluated. Advanced relevant studies are 
required to further explore aspirin use and its likely 
effects. 
 
ASPIRIN AND RISK OF AMD 
As a protective factor 
A retrospective consecutive case series study was also 
conducted to investigate the relationship between the 
use of aspirin or stains and the risk of CNV in the AMD 
patients [65] (Table 1). The use of aspirin or statins was 
reported associated with decreased rates of CNV among 
AMD patients in the case series study.  
The Physician’s Health Study (PHS) [66] is a randomized-
controlled trial (RCT) designed for the effects of aspirin 
and beta carotene in the prevention of cardiovascular 
disease and cancer. A total of 22,071 US participants 
were enrolled in the baseline and a minimum of 7 year 
follow-up was conducted. The results of PHS tend to 
exclude beneficial effects on the treatment of AMD. 
However, in the hypertension group, aspirin use might 
reduce the incidence of AMD ([relative risk] RR: 0.35; 
95% CI: 0.15 to 0.83) after other risk factors have been 
adjusted. The hypertension group also revealed mild 
protective effects compared with the non-hypertension 
group. This finding provides the rationale for the 
advanced research about the association between 
aspirin, cardiovascular disease and AMD. 
As a risk factor 
The European Eye Study, which is a population-based 
cross-sectional study, focused on the relationship 
between aspirin use and incidence of AMD [67]. A total 
of 4691 participants of 65 years or older from 7 centers 
in northern to southern Europe were enrolled in the 
study. The results demonstrated that frequent aspirin 
use was associated with both early AMD and wet late 
AMD, and the risk rose with increasing frequency of 
consumption. The Singapore Indian Eye Study, a study 
enrolling 3207 ethnic Indians aged 40 years or older, also 
reported an increased risk of early AMD in the aspirin 
users [19]. Following adjustment for age, smoking and 
previous cataract surgery, the odds ratio (OR) was 1.50 
(95% CI: 1.01 to 2.22); however, no significant 
association was detected when adjusting for 
cardiovascular disease (OR: 1.38; 95% CI: 0.89 to 2.14). 
This interesting result showed the aspirin use might be 
part of the risk of AMD, however the subjects with a 
cardiovascular disease history should be considered with 
more targeted study. 
There were also the two most recent studies reported by 
Klein et al [21] and Liew [20]. Klein et al reported the 
data from 10 years of follow-up of “The Beaver Dam Eye 
Study”. The association between the use of aspirin and 
the incidence rate of early, late and two subtypes late 
AMD were detected. A small but statistically significant 
increase in the late AMD incidence was identified (hazard 
ratio [HR], 1.63; 95% CI: 1.01-2.63). When considering 
the two subtypes of late AMD, the neovascular AMD and 
pure geographic atrophy, the use of aspirin was 
associated with the incidence of neovascular AMD (HR: 
2.20; 95% CI: 1.20-4.15). However, the results of the fivr 
year follow-up of Beaver Dam Eye Study demonstrated 
aspirin was associated with neither early nor late AMD 
[68]. Comparing the results of different follow-up 
durations in the same clinical trial, a possible explanation 
is that the effect of aspirin on the incidence of AMD is 
quite weak and only a factor in the long term (maybe 10 
years) for an indicator of a significant harmful effect. As 
the first study reported, regarding the increased rate of 
AMD in the aspirin users, this study was also questioned 
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by the definition of the aspirin use and the potential bias 
in the study structure [69]. Apart from the existing 
limitations, the conclusions of this study would provide 
us with viable data. Another study, which was the 
Australian population-based cohort with a 15 year 
follow-up, reported a similar result as Klein’s study [20]. 
The association between aspirin use and risk of 
neovascular AMD (OR: 2.46; 95% CI: 1.25-4.83) was 
detected but not with the geographic atrophy (OR: 0.99; 
95% CI: 0.59-1.65). The relevant confounding factors, 
such as age, gender, smoking, history of cardiovascular 
disease, were adjusted and it concluded that regular 
aspirin use is an independent risk of AMD. 
As an unrelated factor 
A cross-sectional study in Korea was conducted to 
explore the potential risk factors and aspirin was 
reported to be not associated with the risk of AMD [70]. 
The Blue Mountain Eye Study is population-based cohort 
study about the visual and common eye diseases in the 
urban population aged over 49 years [71]. A total of 3654 
participants were in the baseline and a 5 year follow-up 
was conducted. The use of aspirin was not associated 
with the incidence of AMD, in neither the baseline (OR: 
0.9; 95% CI: 0.4 to 0.9) nor the follow-up (OR: 1.3; 95% 
CI: 0.8 to 2.0). In the different frequency aspirin intake 
groups (less than once per week and once per week or 
more), the OR values were not statistical different. In a 
matched-pair case-control study, the epidemiological 
risks of neovascular AMD were detected [72]. The 
extremely discordant sib-pair study design made the 
conclusions persuasive while the use of aspirin was not 
associated with the risk of AMD according to the results. 
However, this study did not provide more detailed data 
about the use of aspirin and advanced discussions were 
limited. The Age-Related Eye Disease Study (AREDS) is a 
study of great importance in the study of AMD [73]. The 
use of aspirin was also mentioned in the reports of the 
AREDS and no positive result was detected. It would be 
significant to analyze this part of the data in advanced 
studies since interesting results might be attained. A 
matched case-control with 18,007 participants enrolled 
was conducted to explore the relationships of different 
frequently used drugs and incidence rate of AMD [74]. 
This large sample data was from the General Practice 
Research Database (GPRD) of the United Kingdom and no 
association was detected in this study as well. 
The Women’s Health Study (WHS) [75] is a RCT about the 
effects of the adoption of 100 mg of aspirin on alternate 
days. In this RCT, 39,876 females aged 45 years or older 
were enrolled and over 10 years of treatment and follow-
up were conducted. The outcome was that AMD was 
responsible for a reduction in best-corrected visual acuity 
to 20/30 or less. This study was different from the 
preceding studies. The results of this large-scale study 
showed that the use of aspirin is neither beneficial nor 
harmful to the development of AMD. Although RCT 
design could discharge the potential bias and 
confounding factors, credible conclusions could be 
reached. 
Meta-analysis is an effective way to pool the existing 
consubstantial studies together and provide more 
powerful evidence. We have conducted a meta-analysis 
about the use of aspirin and risk of AMD [18]. Through 
pooling 10 existing studies (2 RCTs, 4 case-control studies 
and 4 cohort studies), we concluded that aspirin use 
provided neither beneficial nor harmful effects on AMD. 
However, this conclusion should be considered with 
reasonable doubt because of the various studies’ 
limitations. 
Aspirin and ocular hemorrhage in AMD 
As an anticoagulant, aspirin was reported associated with 
the increased risk of hemorrhage, especially the 
gastrointestinal area [76]. Aspirin was regarded as a risk 
factor of ocular hemorrhage [17, 77]. A report of 15 cases 
of ocular hemorrhage in the AMD demonstrated a 
potential risk of aspirin use [77]. Another study 
demonstrated that aspirin used in the neovascular AMD 
would raise the risk of massive intraocular hemorrhage. 
It also documented that aspirin should be prescribed only 
for absolute systemic indications [78]. However, this 
opinion was challenged by other studies, in which the 
association between aspirin use and risk of ocular 
hemorrhage was not detected [16, 79]. A retrospective 
case series of 520 patients about the safety of the 
intravitreal anti-VEGF agent therapy, aspirin was found 
not to be a risk of ocular hemorrhage [79]. However, no 
accordant conclusion has been universally reached. More 
advanced studies in the future will provide us with a 
better understanding of the overall etiology. 
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CONCLUSION 
The relationship between aspirin and risk of AMD has 
long been suggested and it drew more attention 
following association between aspirin use and risk of 
AMD was reported. The experimental evidence, as seen 
today, is extremely limited and the presumptions that 
have been made are not based on persuasive empirical 
data. Future experiments might provide novel 
perspective on this issue. The evidence from clinical 
studies is abundant; however, no unified conclusion has 
been reached. Several problems, such as the definition of 
aspirin use, the inclusion and exclusion of the 
participants and the required long-term follow-up, made 
it hard to conclude the confirmatory relationship 
between aspirin use and AMD. It also should be noted 
that aspirin use might be related with increased risk of 
ocular hemorrhage in the AMD patients, while this 
association is still under investigation. These existing 
results should be challenged and acknowledged by more 
well-designed, large-scale and long-term follow-up 
studies. As a widely used drug, aspirin is important in the 
treatment of several systemic diseases. Aspirin use in the 
AMD patients should be based on a consultation. 
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